Prana Biotechnology soars on Alzheimer's trial data. Cadence re-submits NDA. After the bell, Array BioPharma flys on Novartis agreement Print E-mail
By BioMedReports.com Staff   
Monday, 19 April 2010 19:26
Below is a list of the companies that made news in the healthcare sector on Monday, April 19, 2010.

Prana Biotechnology (NASDAQ:PRAN) (ASX:PBT) soared today after the company announced that the authoritative scientific journal, Journal of Alzheimer's Disease, published an article on April 19 about Prana's lead drug candidate for Alzheimer's disease, PBT2, providing new analysis that it is effective in reversing dementia symptoms. The analysis, conducted by Professor Ashley Bush of The Mental Health Research Institute and The University of Melbourne, Australia, is based on tracking and ranking the responses of each individual patient, rather than only groups of patients, in Prana's PBT2's Phase IIa Alzheimer's disease clinical trial.

The results of the Phase IIa clinical trial, previously reported in The Lancet Neurology (July 2008 and an erratum in July 2009), showed that patients with mild Alzheimer's Disease treated with 250mg of PBT2, experienced an overall statistically significant improvement in Executive Function on a Neuropsychological Test Battery (NTB) within 12 weeks of treatment.

"Improvements in Executive Function is strongly related to improvement in daily function and to the quality of the daily life of patients," noted Dr. Jeffrey Cummings, Director, Alzheimer Disease Research Center, UCLA, and Chairman of Prana's Scientific Advisory Board.

"Very few drugs in clinical development have been able to bring these benefits to Alzheimer's Disease patients. I am very encouraged by these findings," concluded Dr. Cummings.

The Journal of Alzheimer's Disease paper reports the results of a post-unblinding analysis of the cognitive data that was not included in the original paper. The objective of the analysis was to see how individual patients who were receiving PBT2 responded compared to the individual patients who only received placebo. Importantly, even placebo patients showed some improvement in the tests because of a 'learning effect' of repeated testing. This new analysis has adjusted for this and demonstrated that: 1) 81% of patients on the 250mg dose of PBT2 responded better on the Executive Factor NTB score than the best performing patient on placebo. 2) 41% of patients on the 250mg dose of PBT2 responded better on the overall Composite NTB score than the best performing patient on placebo.

Shares of Prana raced higher, surging $1.06 or 78.52%, closing the day at $2.41.

Cadence Pharmaceuticals, Inc. (Nasdaq:CADX) moved higher today after the company announced that, based on feedback received during a meeting with the U.S. Food and Drug Administration (FDA) on April 16, 2010, it plans to re-submit a New Drug Application (NDA) for its investigational product candidate, OFIRMEV™ (acetaminophen) injection, within the next 30 days.

The April 16 meeting was a Type A meeting held among the FDA, Cadence, and its third party manufacturer to discuss the deficiencies outlined in the Complete Response letter related to an inspection of the facility used to manufacture OFIRMEV.

"We believe that last week's meeting with FDA was an important step forward to address the observations from the FDA's inspection of our third party manufacturer's facility and move toward potential approval of OFIRMEV," stated Ted Schroeder, President and CEO. "Based upon our discussions with the agency, we believe that it is appropriate to promptly resubmit the NDA for OFIRMEV and intend do so within the next 30 days."

At the meeting, the FDA did not request any additional information related to the NDA, including any new stability studies. The agency will determine the type of resubmission (Class 1 or Class 2) and resulting review timeline (two months or six months, respectively) after the NDA is resubmitted. Cadence will continue to work with its third party manufacturer to ensure that the observations from the FDA's inspection of the manufacturing facility for OFIRMEV are resolved in a timely manner.

Shares jumped more than 13% or $1.26, closing the day at $10.45.

Array BioPharma Inc. (Nasdaq: ARRY) flew after the bell today after the company announced that it has entered into an agreement with Novartis for the worldwide development of the small-molecule MEK inhibitors ARRY-162, currently in a Phase 1 cancer trial, its back-up, ARRY-300, and other MEK inhibitors.

Under the terms of the agreement, Array will initially receive $45 million comprising an upfront and milestone payment and is eligible to receive an additional $422 million if certain clinical, regulatory and commercial milestones are achieved. In addition, Array plans to co-develop ARRY-162 in one or more specific indications and fund a portion of development costs. The agreement provides Array with double-digit royalties on sales of approved drugs outside of the U.S., with a significantly higher royalty rate for U.S. sales provided that Array meets its co-funding obligations. Array also has a co-detailing right in the U.S. for approved drugs.

"This agreement with Novartis is a major advance in our strategic objective to become a fully integrated, commercial-stage biopharmaceutical company," said Robert E. Conway, Chief Executive Officer, Array BioPharma. "We believe ARRY-162 will benefit from the additional resources of a major pharmaceutical company to rapidly maximize its promise as a cancer treatment, both as a single agent and in combination therapy. Novartis is the right partner because of its track record in developing and commercializing important new cancer therapies."

Shares of Array were up more than 33% as more than 1 Million shares were traded in the after hours market. After closing the regular session at $3.02, shares touched $4.79 in the after market before settling at $4.03.

In other news after the market closed:

Amgen (Nasdaq:AMGN) announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL. These molecules have a comparable mechanism of action to denosumab.

ICU Medical, Inc., (Nasdaq:ICUI), a leading low cost manufacturer of safe medical connectors, custom medical products and critical care devices, announced results for the first quarter ended March 31, 2010.

First quarter of 2010 revenue increased 18.5% to $64.4 million, compared to $54.3 million in the same period last year. Net income for the first quarter of 2010 was $4.3 million, or $0.30 per diluted share, as compared to net income of $7.1 million, or $0.47 per diluted share, for the first quarter of 2009.

Scott Lamb, ICU Medical's Chief Financial Officer, said, "We are pleased with our top-line growth during the quarter, which was driven by strong performance of CLAVEs, Custom Sets and critical care. Domestic distributor and direct sales were up 184% and international sales increased 53% year over year."

CombiMatrix Corporation (Nasdaq:CBMX) announced after the bell today that it is implementing a restructuring plan to significantly reduce operating costs, increase the focus on the Company's diagnostic services business and transition senior management. After the restructuring, CombiMatrix will be focused on its diagnostics services business, including increasing utilization of its existing tests, expanding the test menu, increasing the number of customers and partners, and improving reimbursement for its testing services. Management and operations at CombiMatrix's diagnostic laboratory in Irvine, CA will not be affected by this restructuring. Specific components of the plan and additional details will be presented at the company's second quarter earnings call scheduled for May 11, 2010, if not sooner.

XOMA Ltd. (Nasdaq:XOMA), presented results showing that XOMA's antibody to interleukin-1 beta (IL-1 beta), XOMA 052, was highly effective in reducing production of a protein that supports the proliferation of cancerous human myeloma cells in vitro. These results are consistent with a 47 patient clinical trial in early-stage myeloma patients which demonstrated that IL-1 blockade with IL-1 receptor antagonist Kineret(R) (anakinra) in combination with standard therapy improved progression-free survival..

In news from earlier in the day:

Acura Pharmaceuticals, Inc. (Nasdaq:ACUR) soared ahead of its April 22, 2010 FDA Advisory Committee meeting to discuss the New Drug Application ("NDA") for Acurox(R) (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone. The scheduled meeting will be a joint meeting of the Anesthetic and Life Support Drugs and the Drug Safety and Risk Management Advisory Committees. Acurox(R) is an investigational new drug product and is not approved for marketing or commercial distribution. Shares were up more than 34% on the day, surging $2.04 to $7.91.

Amylin Pharmaceuticals, Inc. (Nasdaq:AMLN) today reported financial results for the quarter ended March 31, 2010. The Company reported total revenue of $174.1 million for the quarter ended March 31, 2010, which includes net product sales of $172.3 million. Non-GAAP operating loss was $3.8 million for the quarter ended March 31, 2010, compared to $19.9 million for the same period in 2009. GAAP net loss was $38.2 million, or $0.27 per share, for the quarter ended March 31, 2010, compared to $47.0 million, or $0.34 per share, for the same period in 2009. At March 31, 2010 the Company held cash, cash equivalents and short-term investments of $598.3 million. "With the submission of our BYDUREON response this week, we are preparing to make this revolutionary treatment option available this year to the millions of patients living with type 2 diabetes," said Daniel M. Bradbury, president and chief executive officer, Amylin Pharmaceuticals. "We remain focused on driving revenue from our currently marketed products, BYETTA and SYMLIN, and continue to exercise financial discipline so that we remain on track to generate sustainable positive operating cash flow by year end."

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that Firdapse™ (3,4-diaminopyridine) is now commercially available in the European Union (E.U.) for the treatment of the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). Launching immediately in Germany and the UK, the company expects to subsequently launch Firdapse in all major European markets by the end of 2010. Firdapse received marketing approval in the E.U. for the treatment of LEMS in December 2009 and is the first approved treatment for this indication, thereby conferring orphan drug protection and providing ten years of market exclusivity in Europe.

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present and separately participate in a cancer immunotherapy panel discussion at the World Vaccine Congress, which will take place April 19-22 in Washington, D.C.

Boston Scientific Corporation (NYSE:BSX) today announced that it has entered into a four-year exclusive marketing agreement with Bladder Health Network (BHN), a privately held company offering advanced testing solutions for urinary incontinence. BHN offers an integrated diagnostic solutions platform that combines software, staffing, equipment, supplies and results analysis, providing physicians and their patients with greater access to testing, interpretation and treatment options for urinary incontinence and other problems related to the urinary system.

Celldex Therapeutics, Inc. (Nasdaq: CLDX), an antibody-based combination immunotherapy company, today announced that CDX-1127, a preclinical therapeutic antibody program for oncology indications, will be the subject of a poster presentation at the 2010 American Association for Cancer Research (AACR) 101st Annual Meeting in Washington, DC on Wednesday, April 21, 2010.

Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) today announced that it met with and received feedback from the rapporteurs and the European Medicines Agency's medical reviewers regarding a proposed filing of a Marketing Authorization Application for pixantrone in the European Union to treat relapsed/refractory aggressive non-Hodgkin's lymphoma. The rapporteurs, who are assigned by the EMEA, are responsible for providing scientific advice on the evaluation of medicinal products. The feedback was supportive of filing on the basis of the PIX301 trial and the Company expects to submit the MAA in September 2010. "Both the rapporteurs and medical reviewers felt that the totality of the efficacy data from the PIX301 trial including the complete response rate, overall response rate, progression-free survival and the trend in overall survival supports a MAA submission and review," said Jack Singer, M.D., Chief Medical Officer of the Company.

Cord Blood America, Inc. (OTC Bulletin Board:CBAI.ob), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced that it has signed a Letter of Intent to purchase controlling interest in BioCells, Inc., headquartered in Argentina, with affiliates under development in Peru, Colombia, Bolivia, Panama and Puerto Rico.

BioCells, the second largest stem cell storage company in Argentina, is profitable, with annual revenues in 2009 of $1.2 million (USD), and 12 locations throughout that country, plus recent expansion into Uruguay and Paraguay. On February 8, 2010, Cord Blood America announced that BioCells finalized an agreement to process and store cord blood specimens with Cord Blood America in Las Vegas.

Elan Corporation, plc (NYSE: ELN) reported today that the company has decided to explore the possibility of a separation of its Elan Drug Technologies (EDT) business. If executed, any transaction would create two distinct publicly listed companies: Elan BioNeurology and EDT, with each entity being a leader in its field of expertise. The purpose of this exploration is to accurately assess the opportunity and impact on shareholder value.

On an operating basis, both EDT and BioNeurology are now profitable. Each represents vastly different investment propositions, and each generates distinct and on-going capital requirements for utilization against a broad array of potential opportunities.

The company’s review will include detailed assessment of the possible separation, including timing, market conditions and the impact on all of its key constituencies. The Company expects to make a decision whether to proceed in the coming months. No specific timetable has been set for completion of the review and there can be no assurances that such a transaction will take place.

EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) today announced that the commercial launch of Ceplene® (histamine dihydrochloride) will take place in the United Kingdom on April 20, 2010 in conjunction with the British Society for Haematology 50th Annual Scientific Meeting in Edinburgh, Scotland. Ceplene is approved in the European Union for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first remission.

Generex Biotechnology Corporation (Nasdaq:GNBT), today announced that it has established an action plan for obtaining cost reimbursement coverage for Generex Oal-lyn(TM), including the development of an insurance product that covers the costs of Generex Oral-lyn(TM) and any additional and/or comparable diabetes products. Some of the objectives in the action plan will include: the creation of a prospectus for use with Insurance Underwriters; the development of cost and risk assessment profile; identifying potential underwriters; and the creation of supporting actuarial and marketing materials.

Hospira, Inc. (NYSE:HSP) and Javelin Pharmaceuticals, Inc. (NYSE - Amex: JAV), today announced that the companies have entered into a definitive merger agreement providing for the acquisition of Javelin by Hospira for $2.20 per share in cash, or approximately $145 million. Hospira expects to commence a tender offer for all outstanding shares of Javelin common stock on or about April 21, 2010, in accordance with the terms of the merger agreement.

The acquisition of Javelin would allow Hospira to take advantage of synergies between Javelin's main product candidate, Dyloject™, a post-operative pain management drug currently awaiting U.S. Food and Drug Administration (FDA) approval, and Hospira's proprietary sedation agent, Precedex™. Both drugs are marketed to anesthesiologists, enabling Hospira to leverage its Precedex sales force to promote Dyloject.

"Dyloject would broaden Hospira's pain management portfolio and offers attractive revenue and margin prospects," said Ron Squarer, chief commercial officer, Hospira. "Dyloject is also a very good fit with Precedex, and further demonstrates Hospira's strong commitment to the acute-care space."

 As result of the aquisition of Javelin by Hospira, Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the termination, effective as of Friday, April 16, 2010, of its merger agreement with Javelin . In accordance with the terms of the merger agreement, Myriad Pharmaceuticals is entitled to the payment from Javelin of stipulated expenses of $1.5 million plus a termination fee of $2.9 million, within one business day of the termination, and in accordance with the terms of the $8.5 million Loan and Security Agreement, is entitled to the repayment, in full, from Javelin, of the outstanding balance under the agreement, together with accrued interest thereon, within two business days of the termination.

Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Novartis has withdrawn a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN™) for the treatment of chronic hepatitis C.

The decision to withdraw the application was based on feedback from European regulatory authorities in preliminary response to the EMA application, indicating that additional new data would be requested which could not reasonably be generated within the timeframe allowed in the European Centralized Procedure. Feedback included whether the therapeutic benefit offered by JOULFERON dosed once every two weeks is sufficient relative to risk.

ZALBIN (JOULFERON) is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in 2006. In November 2009, HGS submitted a Biologics License Application (BLA) to the FDA in the United States for ZALBIN dosed every two weeks, which continues under review. HGS and Novartis are also developing ZALBIN dosed every four weeks, and HGS previously reported the positive interim results of a Phase 2b study of this ZALBIN regimen.

Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported the development of a novel protein complex, designated as E1-L-thP1, for targeted delivery of small interfering ribonucleic acids (siRNAs) to diverse solid cancers. E1-L-thP1 was found to internalize in cells that express the TROP-2 antigen, suggesting the binding ability of hRS7 remains intact in the fusion protein. More importantly, it effectively delivered siRNAs into TROP-2-expressing cancer cells, causing cell death. Further evaluation of the in vitro and in vivo efficacy of E1-L-thP1 for delivery of CD74- and CEACAM6-specific siRNAs to treat TROP-2-expressing pancreatic cancer is ongoing. In a separate release Immunomedics reported today at the 101st Annual Meeting of the American Association for Cancer Research (AACR) results from two studies aimed at improving the design of antibody-SN-38 conjugates for targeted cancer chemotherapy.

Lannett Company, Inc. (NYSE AMEX: LCI) tracked higher today after the company announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Ondansetron Injection USP, 2 mg/mL, Multi-Dose Vials. Ondansetron Injection USP, 2 mg/mL is the generic equivalent of GlaxoSmithKline’s Zofran® Injection, 2 mg/mL. For the 12 months ending December 2009 U.S. sales of Ondansetron Injection USP, 2 mg/mL were approximately $58 million at Average Wholesale Price (AWP). A launch date for the product has not yet been set.

"Ondansetron Injection is the first injectable product for which Lannett has filed an ANDA and, importantly, the first product candidate approved for marketing from our joint venture with Wintac Ltd.," said Arthur Bedrosian, president and chief executive officer of Lannett. "The addition of an injectable drug to our product offering will enhance our ability to build our hospital-based business." Shares were up on 3.5% on the news.

MDRNA, Inc. (NASDAQ:MRNA), a leading RNAi-based drug discovery and development company, today announced that the Intellectual Property Office of New Zealand (IPONZ) has issued a Notice of Acceptance for patent application 553828, titled "Methods of Treating an Inflammatory Disease by Double-Stranded Ribonucleic Acid." Allowed claims cover small interfering RNAs (siRNA) directed against the tumor necrosis factor (TNF) gene as well as several of the Company's key nucleic acid condensing and delivery peptide motifs in combination with a siRNA directed against TNF. This patent application was filed in 2005 as part of MDRNA's global intellectual property strategy which comprises a broad comprehensive patent portfolio protecting the Company's proprietary siRNA constructs, nucleic acid chemistry, nucleic acid delivery platforms, and its extensive library of siRNAs directed against therapeutic targets.

Micromet, Inc. (Nasdaq:MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that results from studies highlighting pre-clinical advances with its proprietary BiTE antibody technology were presented at the American Association for Cancer Research (AACR) Annual Meeting in Washington, DC.

The Company and its collaborators reported pre-clinical data characterizing new BiTE antibodies targeting 11 tumor-associated antigens, including CEA, EGFR, IGFR-1, cMet and FAP-alpha. The data demonstrate that BiTE antibodies can be generated to target a wide range of tumor antigens of highly different function, size and molecular composition, illustrating the wide applicability of the BiTE antibody technology for the treatment of diverse cancer indications.

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced presentation of results from a preclinical study of its novel oncology drug candidate, M402, in a murine pancreatic cancer model. The data showed thatM402, in combination with gemcitabine, significantly prolonged survival and reduced metastasis as compared to groups treated with saline alone or gemcitabine alone.

Mylan Inc. (Nasdaq:MYL) today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC. This product, which the company expects to begin marketing in the U.S. during the current quarter, will be sold under the Mylan Pharmaceuticals brand. The product will also be sold outside the U.S. in a number of developing countries.

Didanosine Delayed-release Capsules had U.S. sales of approximately $29 million for the 12 months ending Dec. 31, 2009, according to IMS Health.

Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today reported data from a new preclinical study demonstrating that the company's phosphatidylserine (PS)-targeting antibodies reversed immune suppression by tumors and conferred tumor-specific immunity in models of breast cancer. Said Dr. Philip Thorpe, professor of pharmacology at the University of Texas Southwestern Medical Center, a scientific advisor to Peregrine and co-author of this study. "This study shows that the immunosuppressive effects of PS exposed on apoptotic tumor cells can be reversed by PS-targeting antibodies, specifically by reversing the suppression of dendritic cell (DC) maturation caused by the exposed PS. This finding is important since reactivation of the immune system after the primary tumor has been removed is a critical line of defense in fighting cancer recurrence. Additionally, we showed that PS-targeting antibodies have the ability to confer tumor-specific immunity, which could lead to the future development of new cancer vaccine regimens."

Sequenom, Inc. (Nasdaq:SQNM) moved higher today after the company announced the launch of its next-generation mass spectrometry system – the MassARRAY® Analyzer 4. This new high performance nucleic acid analysis platform has been designed to meet customer demand for a bench top instrument with greater flexibility across multiple applications, improved reliability and faster performance. With the capability for quantitative gene expression analysis, epigenetic nucleic acid methylation analysis as well as high-throughput genotyping and SNP fine mapping applications, the MassARRAY Analyzer 4 is designed to empower the basic and translational research community to advance findings from basic genetic and biomarker studies toward clinical utility in diagnosis, prognosis and monitoring of diseases. The MassARRAY Analyzer 4 system will initially be offered to research-use-only (RUO) laboratories, and subject to FDA clearance will be released to CLIA-certified laboratories for the generation and implementation of laboratory-developed tests. Shares of Sequenom were up 4.31% or 25 cents to $6.05.

Sigma® Life Science, the innovative biological products and services brand of Sigma-Aldrich® (Nasdaq:SIAL), today introduced the world's first p53 'knockout' rat model, an important development that is expected to, due to the rat's closer physiological and metabolic similarity to humans, significantly improve timelines for carcinogenicity screening and reduce time to market for therapeutics. "Over the past twelve months, SAGE Labs has been developing novel rat models, in which specific genes associated with defined disease conditions are deactivated or knocked-out, for use in disease research, especially in areas where the existing mouse models poorly mimic human disease," said Dr. Edward Weinstein, director of SAGE Labs.

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the American Association for Cancer Research (AACR) 101st Annual Meeting show that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrates synergy with standard of care therapies such as Avastin in non-small cell lung cancer models; penetrates efficiently into hypoxic (low oxygen) regions of tumors; and inhibits both HIF-1a and JAK/STAT signaling, pathways that are critical to the survival and proliferation of certain cancer types.

"STA-9090 has demonstrated encouraging signs of single-agent activity in our Phase 1 and Phase 2 clinical trials, as well as a manageable safety profile," said Vojo Vukovic, M.D., Ph.D., Senior Vice President and Chief Medical Officer, Synta Pharmaceuticals. "Results presented today further support the potential for STA-9090 in treating a range of cancers, both as a single-agent and in combination with other anti-cancer agents."

YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), movd higher today after the company announced the pre-publication of pivotal preclinical data for CYT387, the company's highly selective and potent JAK1/2 inhibitor, currently in a Phase I/II trial for myelofibrosis. The paper describes work conducted in the laboratory of Dr. Michael Deininger at Oregon Health Sciences University Knight Cancer Institute, Portland, Oregon, which demonstrates that orally-administered CYT387 normalizes the hallmark MPN features of elevated blood cell counts and enlarged spleen size in an in vivo model of the disease. Importantly, blood cell production is shown to return to the bone marrow with drug treatment.

Also Monday:

Alkermes, Inc. (NASDAQ: ALKS) today announced that it will webcast its Research and Development (R&D) Day being held on Monday, April 26, 2010, at the Nasdaq MarketSite.

CDEX Inc. (OTCBB: CEXI) announces that its Board of Directors has appointed Donald W. Strickland as its new CEO.Mr. Strickland, a Director of the Company, has served in senior management positions for over 30 years and has successfully developed businesses for both large public companies and technology startups.

Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, April 29, 2010 at 9 a.m. ET to discuss the company's first quarter 2010 financial and operational results.

Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a live webcast and conference call at 10:00 AM EDT on Tuesday, April 27, 2010 to review first quarter 2010 results and to present an updated slide presentation of the company's current status and outlook.

Eli Lilly and Company (NYSE:LLY) today announced financial results for the first quarter of 2010.

Humana Inc. (NYSE: HUM) announced today that it will extend health insurance coverage for young adults currently covered by their parents’ Humana health plans during what otherwise could have been a gap in their coverage.

Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that it plans to report first quarter 2010 financial results on Monday, May 3, 2010. Inspire's President and CEO, Adrian Adams, and Executive Vice President and CFO, Thomas R. Staab, II, will host a conference call and live webcast on Monday, May 3, 2010 at 10:00 a.m. ET.

Millipore Corporation (NYSE: MIL), a leading provider of technologies, tools and services for the global life science industry, today announced it has begun full commercial shipments of its Scepter Handheld Automated Cell Counter to customers worldwide.

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos is presenting three scientific posters, based on collaborations with Drs. Kenneth Tew and Danyelle Townsend of the Medical University of South Carolina, Charleston, SC, and Drs. C. Marcela Diaz-Montero and Alberto Montero of the Sylvester Comprehensive Cancer Center, University of Miami, Miami FL, at the ongoing American Association for Cancer Research (AACR) 2010 Annual Meeting being held in Washington, DC.

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) approved the daily pill Tarceva® (erlotinib) as a maintanance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.

RegeneRx Biopharmaceuticals, Inc. (NYSE Amex: RGN), a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced today that it intends to offer units consisting of shares of its common stock and warrants to purchase shares of its common stock in a public offering.

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Anastasia Khvorova, Ph.D., Chief Scientific Officer, is presenting at the 101st annual American Association for Cancer Research (AACR) Conference on April 19, 2010. The presentation will not be webcast.

Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) a fully integrated and highly innovative specialty pharmaceutical company engaged in the research and development, and the manufacture and marketing of biopharmaceutical products in China, has announced its financial results for the third quarter ended February 28, 2010.

Vermillion, Inc. (Pink Sheets: VRML) today announced the appointment of Sandra A. Gardiner as Vice President and Chief Financial Officer (CFO). In her role as CFO, Ms. Gardiner will be responsible for leading all aspects of financial management for Vermillion.

Viral Genetics, Inc., (Pink Sheets:VRAL), is relocating its research facilities to the life science cluster in Georgetown, Texas.

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter